Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse

RG Dossa, T Cunningham… - Blood, The Journal …, 2018 - ashpublications.org
Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell
transplantation (HCT) failure, and the prognosis for patients with post-HCT relapse is poor …

The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the …

R Ronsley, A Kariminia, B Ng, S Mostafavi… - Pediatric Hematology …, 2019 - Taylor & Francis
Background: Preclinical studies show that TLR9 agonists can eradicate leukemia by
induction of immune responses in vivo against AML and ALL. These studies demonstrated …

In vitro IL-15-activated human naïve CD8+ T cells down-modulate the CD8β chain and become CD8αα T cells

AJ Esgalhado, D Reste-Ferreira, S Weinhold… - Frontiers in …, 2024 - frontiersin.org
Antigen-driven human effector-memory CD8+ T cells expressing low levels of the CD8β
chain have been previously described. However, little is known on a possible antigen …

An engineered anti-idiotypic antibody-derived killer peptide (KP) early activates swine inflammatory monocytes, CD3+ CD16+ natural killer T cells and CD4+ CD8α+ …

L Ferrari, P Martelli, R Saleri, E De Angelis… - … and Infectious Diseases, 2020 - Elsevier
This study evaluated the early modulation of the phenotype and cytokine secretion in swine
immune cells treated with an engineered killer peptide (KP) based on an anti-idiotypic …

[PDF][PDF] Comparative Immunology, Microbiology and Infectious Diseases

RW Vergara, FM Galleguillos, MG Jaramillo… - … and Infectious Diseases, 2016 - core.ac.uk
This study evaluated the early modulation of the phenotype and cytokine secretion in swine
immune cells treated with an engineered killer peptide (KP) based on an anti-idiotypic …